MO - Altria Group, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
56.75
+1.03 (+1.85%)
As of 12:16PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close55.72
Open55.51
Bid56.88 x 800
Ask56.89 x 1200
Day's Range55.51 - 56.96
52 Week Range42.40 - 66.04
Volume3,214,191
Avg. Volume13,275,771
Market Cap106.259B
Beta (3Y Monthly)0.27
PE Ratio (TTM)15.42
EPS (TTM)3.68
Earnings DateApr 25, 2019
Forward Dividend & Yield3.20 (5.58%)
Ex-Dividend Date2019-03-22
1y Target Est57.47
Trade prices are not sourced from all markets
  • CVS introduces CBD-based products in 8 states
    Yahoo Finance Video2 hours ago

    CVS introduces CBD-based products in 8 states

    CVS has announced it will begin to sell topical CBD products at stores in Alabama, California, Colorado, Illinois, Indiana, Kentucky, Maryland and Tennessee. Yahoo Finance’s Dan Roberts, Akiko Fujita, Sibile Marcellus, and Alexis Keenan talk about the pharmaceutical chain’s decision to go green.

  • FDA's Departing Gottlieb Keeps The Heat On E-Cig Market
    Yahoo Finance Video21 hours ago

    FDA's Departing Gottlieb Keeps The Heat On E-Cig Market

    E-cig industry faces pressure in San Francisco. Yahoo Finance's Zack Guzman & Melody Hahm, along with Digiday Platforms Reporter Kerry Flynn discuss.

  • San Francisco considers new law to ban e-cigarette sales
    CNBC Videosyesterday

    San Francisco considers new law to ban e-cigarette sales

    The "Squawk Box" news team discusses some of the morning's most provocative headlines.

  • Altria falls on report San Francisco officials seeking Ju...
    CNBC Videos2 days ago

    Altria falls on report San Francisco officials seeking Ju...

    Altria shares are falling after a report that San Francisco officials are looking into cracking down on Juul. CNBC's Aditi Roy reports.

  • Will Cronos Group Earnings Get an Altria Bump?
    Motley Fool4 hours ago

    Will Cronos Group Earnings Get an Altria Bump?

    With the cigarette giant's investment in the cannabis company complete, it's up to Cronos to perform.

  • These Marijuana Stocks Have Doubled So Far in 2019
    Motley Fool21 hours ago

    These Marijuana Stocks Have Doubled So Far in 2019

    Find out if further gains are around the corner.

  • Benzingayesterday

    Bank Of America Raises Altria Price Target Despite FDA Risk

    Altria Group Inc (NYSE: MO) plunged Tuesday after Food and Drug Administration Commissioner Scott Gottlieb said he's concerned about the slow pace of efforts to curb youth smoking. Gottlieb lamented Juul and Altria’s lack of progress in prohibiting youth access. Lewandowski said she suspects any threats will lose bite over time.

  • Did You Miss Your Chance to Buy Aurora Cannabis Stock?
    InvestorPlaceyesterday

    Did You Miss Your Chance to Buy Aurora Cannabis Stock?

    Shares of Aurora Cannabis (NYSE:ACB) have been soaring lately, up 25% in just a few trading sessions. Because of this giant move, investors are wondering if now's the time to get in on ACB stock or if a 25% rally means they missed their chance.Source: Shutterstock What's the verdict?I wouldn't say there's no upside left, but the risk-reward profile has certainly muddied. Unfortunately, investors who are suffering a case of FOMO -- a "fear of missing out" -- have no reason to be. There was ample time to buy this name, even after the big rally.InvestorPlace - Stock Market News, Stock Advice & Trading TipsLet's look at the charts to see why. Trading ACB Stock Click to Enlarge There are so many choices in the investing world that I do not like to be a "told you so" person. Meaning that even studious followers of the stock market can't act on everything they see and read. In the case of ACB stock, though, perhaps investors can extract a lesson. * 7 Video Game Stocks on Steep Discount Notice how the stock gapped higher by about $1 per share last week, closing near $9 after previously closing near $8. Many would argue that this ~12.5% gain was simply too much of a rally and they'd have to move on to something else. I needed to see how ACB stock would trade over the next few days, too, as I don't want to chase a double-digit move.The next day ACB stock put in an "inside day." That's where a stock's daily range trades within the range of the prior day. Notice on the chart above how the second candle following the big gap-up candle is within its range? After a big rally like this, that's a great consolidation pattern that bulls want to see. It shows that longs aren't winning to sell and shorts don't have enough "oomph" to drive it down.The next day, ACB stock began what looked like another inside day, before rocketing higher. In other words, this price action allowed investors to hop on before an 11% move higher.So what now?Shares of Aurora Cannabis stock are stretching into overbought territory. However, that does not mean it cannot continue higher. I wouldn't mind seeing how ACB stock does over the next few sessions and if we get a slight pullback before moving higher again.Keep in mind, ACB stock has breached $12 more than once in the past 12 months. Perhaps it's on its way of doing it a third time. Valuing Aurora Cannabis StockSo what got Aurora Cannabis stock rallying so strongly anyway? The company brought activist investor Nelson Peltz on board to advise on partnerships and global expansion.They didn't pick a bad advisor, either. Peltz has a long list of contacts and the hedge fund manager is a master in the consumer packaged goods space. Whether this leads to a partnership with a well-known blue-chip company or not remains to be seen. But adding him in this role certainly doesn't hurt Aurora's chances.That said, we're still very much in the "land grab" phase of the cannabis market. While growth is impressive -- as ACB stock grew sales 339% year-over-year last quarter -- the valuations do not support these names. For instance, while revenues more than quadrupled last quarter, sales came up just short of $39 million. With a $10 billion valuation, that growth better continue for some time in order for it to be justified.But if there wasn't an opportunity here, we wouldn't have Constellation Brands (NYSE:STZ) taking a multi-billion stake in Canopy Growth (NYSE:CGC) or Altria (NYSE:MO) doing the same thing with Cronos Group (NASDAQ:CRON). There's money to be made and an opportunity to be had with states and countries legalizing marijuana, both for medical and recreational use.That said, it's not a short-term or risk-free endeavor for investors.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CGC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Did You Miss Your Chance to Buy Aurora Cannabis Stock? appeared first on InvestorPlace.

  • Reutersyesterday

    U.S. vaping products supplier Greenlane files for IPO

    Vaping products supplier Greenlane Holdings Inc filed for an initial public offering with U.S. regulators on Wednesday, in the backdrop of both growing investor interest and rising regulatory scrutiny into the e-cigarette industry. Greenlane sells vaping products and accessories to over 6,600 independent smoke shops, regional retail stores and a number of licensed cannabis cultivators, processors and dispensaries. Greenlane's move to tap equity markets comes as traditional tobacco companies make major investments into e-cigarettes.

  • Buy these tobacco stocks for smokin’ profits
    MarketWatchyesterday

    Buy these tobacco stocks for smokin’ profits

    OUTSIDE THE BOX Tobacco stocks got a bounce earlier this month on news of the resignation of Food & Drug Administration chief Scott Gottlieb. This made sense because he has had it in for vaping, menthol cigarettes and nicotine levels in cigarettes.

  • InvestorPlaceyesterday

    Who’s Made The Right Call On Cronos Group Stock? Altria or Analysts?

    So far, 2019 has been good to Cronos Group (NASDAQ:CRON). Its share price has more than doubled this year. And the CRON stock gains make some sense.Indeed, as I wrote in December, the $1.8 billion investment in CRON stock by Altria (NYSE:MO) seems to be a game-changer. Among cannabis stocks, only Canopy Growth (NYSE:CGC), with $4 billion in hand from its deal with Constellation Brands (NYSE:STZ), looked to be in a stronger financial position. And yet, amid a market sell-off, investors largely shrugged at Cronos Group stock.That's changed in 2019, obviously, and perhaps it's changed a little too much. I still believe CRON stock needs to settle down. And I'm not alone. Wall Street has turned notably bearish on the shares in recent weeks. Ahead of Cronos Group earnings next week, those analysts might have a point.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cautious Turn on CRON StockAs MarketWatch pointed out last week, the Street on the whole actually sees downside ahead for CRON shares. Some 11 analysts on average have a target price of $20.30, or 6.6% below current levels.And recent coverage hasn't been all that positive. Per MarketWatch, BMO Capital Markets downgraded CRON to underperform. Analyst Tamy Chen pointed out that CRON trades at 80x EBITDA estimates -- two times the multiple sported by Aurora Cannabis (NYSE:ACB) and higher than Canopy Growth.Chen isn't alone. GMP Securities cut Cronos to hold earlier this month. Cowen (NASDAQ:COWN) initiated at neutral. Jefferies Financial Group (NYSE:JEF) began its coverage of Cronos Group stock with an underperform in late February (though CRON stock rose anyway). * Top 7 Service Sector Stocks That Will Pay You to Own Them To be sure, the Street isn't as always right. And even bearish analysts -- including the team at Jefferies -- have pointed to a massive opportunity in both recreational and medicinal cannabis.But for investors looking for the best cannabis play, it's worth noting that the analysts aren't just focused on valuation. BMO has pointed out that Cronos is trailing other Canadian producers in building out capacity. According to Yahoo! Finance, Jefferies cited concerns about when, exactly, Cronos would spend the funds from Altria -- and how much support the tobacco giant would give the pot producer in the early going.While it's easy to dismiss analyst concerns -- and, again, it's far from guaranteed that the Street is correct -- the factors driving the downgrades should be given some consideration. This isn't a case of analysts simply hollering about near-term valuation metrics, or arguing that cannabis stocks represent some sort of bubble.The common thread in recent coverage isn't that Cronos Group is failing or that it has no opportunity. Rather, the worry is that the company isn't moving fast enough in an industry where being a first mover increasingly looks like a key advantage. Earnings and Cronos Group StockIt's not just analysts who are making that point. InvestorPlace contributor Luke Lango made the case last month that Canopy Growth, not Cronos, was the best play in cannabis. One reason: CGC stock is actually cheaper on a per-kilogram basis.That can change if Cronos ramps production and puts its Altria funds to work. So far, however, that hasn't quite been the case. In fact, the company earlier this month swapped its shares of privately held Whistler Medical Marijuana for shares in Aurora Cannabis. That deal highlights the difference between the two companies. * 15 Stocks That May Be Hurt by This Year's Big IPOs Aurora's strategy clearly is to take as many shots at as many opportunities as possible in the shortest amount of time. With that strategy, it's possible that Aurora is taking on too many projects. But in a fluid market (from both a competitive and regulatory perspective), and one with multiple products (recreational, medical, CBD, edibles, etc.), Aurora is trying to gain exposure to as many markets as possible.Cronos doesn't have to take the same path as Aurora. But with the stock near the highs -- and triple late November levels -- it's going to need to show something with earnings next week. That may be discussion of what exactly it plans to do with its $1.8 billion in newly received cash. It may be clarity on Altria's role. (Note that Altria's senior director of corporate strategy is joining Cronos as chief financial officer, perhaps a step in the right direction.) It may be talk of additional M&A, after a huge win on the Whistler deal. (Cronos appears to have invested CAD$4 million [$3 million] in the company - and received C$175 million in Aurora stock.)Whatever it is, with the highest valuation in the cannabis stock, the status quo isn't enough. Cronos needs to post an impressive earnings report next week -- and not just in the numbers. Rather, the company needs to convince investors that it can take advantage of its cash, and put that cash to work to drive growth. It won't be easy - and at these prices, expectations are going to be high.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise Compare Brokers The post Who's Made The Right Call On Cronos Group Stock? Altria or Analysts? appeared first on InvestorPlace.

  • The Wall Street Journal2 days ago

    [$$] AB InBev Names New Chairman; 3G CEO to Exit Board

    Anheuser-Busch InBev named Marty Barrington its new chairman and said the CEO of private-equity firm 3G Capital was leaving its board, part of a broader shake-up at the world’s biggest brewer as it struggles ...

  • CNBC2 days ago

    Altria shares fall after FDA's Gottlieb describes 'difficult' meeting on Juul

    Altria made a $12.8 billion investment in the e-cigarette maker late last year. The FDA commissioner has accused Juul and Marlboro-maker Altria executives of reneging on promises they made to help combat teen vaping.

  • Altria (MO) Hurt by Low Cigarette Sales, Inclines Toward RRPs
    Zacks2 days ago

    Altria (MO) Hurt by Low Cigarette Sales, Inclines Toward RRPs

    Altria (MO) is undertaking efforts to expand in the RRPs space amid receding cigarette shipping volumes.

  • Is Cronos Group Stock Too Expensive to Buy?
    Motley Fool2 days ago

    Is Cronos Group Stock Too Expensive to Buy?

    The analysts are down on Cronos. Should you be, too?

  • Altria (MO) Outpaces Stock Market Gains: What You Should Know
    Zacks3 days ago

    Altria (MO) Outpaces Stock Market Gains: What You Should Know

    Altria (MO) closed at $57.30 in the latest trading session, marking a +0.97% move from the prior day.

  • Why Tilray Stock’s Q4 Report Shouldn’t Be About Q4 Numbers
    InvestorPlace3 days ago

    Why Tilray Stock’s Q4 Report Shouldn’t Be About Q4 Numbers

    The ongoing cannabis stock craze will likely see another move after Monday's closing bell. That's when Canadian pot conglomerate Tilray (NASDAQ:TLRY) is slated to report its fourth-quarter numbers, perhaps pushing Tilray stock out of the sideways rut it's been in since December.Source: Shutterstock Which direction TLRY ends up moving (if it moves at all) remains in question. While investors will certainly be interested in seeing how much marijuana Tilray sold during the quarter -- recreational marijuana in particular, the real scrutiny will be on company has continued to evolve. For Tilray, Q4 was a period to form partnerships and make acquisitions. The rhetoric about that dealmaking will be the key to overcoming any valuation problems or worries about sustained losses for Tilray stock. Tilray Earnings PreviewFor the quarter ending on December 31st, analysts expect TLRY to report revenue of $15.9 million, although some outside estimates put the figure closer to $18.3 million.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 3 Earnings Reports to Watch Next Week That still won't be enough to pull the young, budding company out of the red though. Those same pros are also calling for a loss of 15 cents per share of Tilray stock -- a modest improvement on the loss of 20 cents per share booked during Q3 of last year.It is a work in progress, as is the case with all cannabis stocks at this time. Actual net profits may still be a distant goal.The industry is making progress to that end, however, with some help from much bigger friends. Pot-Laced PartnershipsConstellation Brands (NYSE:STZ) got the pot-partnership ball rolling in August of last year, via a $4 billion investment in Tilray rival Canopy Growth (NYSE:CGC). Altria Group (NYSE:MO) followed suit in December, making a $1.8 billion investment in Cronos Group (NASDAQ:CRON).Both deals were largely intended to secure a stake in the marijuana market, even without knowing exactly what the future may hold. Though marijuana is now legal in Canada and several U.S. states, it remains illegal at the Federal level in the U.S.The newly-formed partnerships are aiming to innovate new products. Tilray Is Moving SlowerTilray has thus far lagged the innovation and team-up movement. And although the Canadian government legalized cannabis in mid-October, Tilray didn't actually sell any recreational cannabis during the first two weeks it was allowed to do so.Tilray has been busy building its team though. Near the end of last year it acquired licensed producer Natura Naturals at a cost of $26.3 million. And, around that same time it inked distribution deals with the pharmaceutical industry, and has agreed to work with Anheuser Busch Inbev (NYSE:BUD) to create and market cannabis-based drinks. In December of last year, the company rounded out its network with a $317 million purchase of Manitoba Harvest.The Q4 report will be the first to include recreational sales, though it still won't reflect the full revenue potential of Tilray.In that light, investors may want to worry less about Q4 numbers and focus more on how it's piecing together its organization in an increasingly competitive environment. Looking Ahead for Tilray StockThe TLRY story is certainly an exciting one, and undoubtedly cannabis has a bright future. But, it remains to be seen if Tilray has a future that's bright enough to merit its $7.0 billion valuation.More than a few investors don't think it does. As of the most recent look, nearly 25% of the stock's float is held as a short position, meaning nearly four million shares of TLRY are held by traders betting Tilray stock will move lower before it moves higher. * 7 Small-Cap Stocks That Make the Grade Those bets could backfire in a big way though. Should the response to Monday's post-close earnings report be a bullish one, a sharp rise in the price of Tilray shares could cause those short-sellers to panic and buy shares to exit their trade, fanning the bullish flames.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 of the Best Stocks to Buy Under $10 * 7 Single-Digit P/E Stocks With Massive Upside * 7 Best Quantum Computing Stocks Trading Today Compare Brokers The post Why Tilray Stock's Q4 Report Shouldn't Be About Q4 Numbers appeared first on InvestorPlace.

  • 3 Marijuana Stocks With a Killer Advantage
    Motley Fool4 days ago

    3 Marijuana Stocks With a Killer Advantage

    Not all marijuana stocks are alike. These three have a competitive edge that their rivals don't.

  • Cronos Group's $1.8 Billion Investment From Altria Has Closed. Now What?
    Motley Fool4 days ago

    Cronos Group's $1.8 Billion Investment From Altria Has Closed. Now What?

    Here's what Cronos Group should do with its new-found fortune.

  • Marijuana Stocks Must Solve This Problem To Win $80 Billion Jackpot
    Investor's Business Daily5 days ago

    Marijuana Stocks Must Solve This Problem To Win $80 Billion Jackpot

    Marijuana stocks face a crucial challenge: How to brand cannabis as marijuana legalization spreads and brings more consumers from the streets into stores.

  • 5 Recession-Proof Stocks
    Motley Fool6 days ago

    5 Recession-Proof Stocks

    Almost no one is thinking about the fifth company, and therein lies opportunity.

  • Philip Morris and Altria: How Do Valuation Multiples Compare?
    Market Realist6 days ago

    Philip Morris and Altria: How Do Valuation Multiples Compare?

    Will Upward Momentum Continue for Altria and Philip Morris?(Continued from Prior Part)Philip Morris’s valuation multiple As the graph below shows, Philip Morris International’s (PM) valuation multiple has increased since the beginning of 2019.

  • Altria and Philip Morris: Do Dividend Yields Look Attractive?
    Market Realist6 days ago

    Altria and Philip Morris: Do Dividend Yields Look Attractive?

    Will Upward Momentum Continue for Altria and Philip Morris?(Continued from Prior Part)Importance of dividends Dividends smoothen out return volatility for shareholders. Both Altria Group (MO) and Philip Morris International (PM) have a history of

  • InvestorPlace6 days ago

    Aurora Cannabis, Nelson Peltz Tie-Up is Ultimately About One Thing

    Credibility. Without it, a growing company in a competitive arena is lost. With it, it can be a steamroller.Not that Aurora Cannabis (NYSE:ACB) was lacking credibility, but now that it has activist investor Nelson Peltz on board as an advisor, the budding company has much more than it did. ACB stock jumped 14% on Wednesday, ultimately because the hedge fund manager will help Aurora speak with all the right people that can help take the organization to the proverbial next level.Other reasons were cited for the big jump in Aurora Cannabis stock, and those weren't necessarily wrong. But, it's the sudden jolt of Peltz-related credibility that fueled the move.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd yes, for some investors who still weren't quite convinced, this could be enough of a reason take a shot on Aurora Cannabis stock. Missing PiecesACB been something of an outlier among its pot peers, actually. Canopy Growth (NYSE:CGC) last year attracted Constellation Brands (NYSE:STZ) as a major stakeholder. Cronos Group (NYSE:CRON) is in bed with Altria Group (NYSE:MO) which now owns 45%. Aurora doesn't have a major partner yet. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% The reasons why aren't exactly clear. The Canadian company has as much to offer an aspiring cannabis player as Cronos or Canopy Growth.Those reasons, however, are also now irrelevant. Peltz has already dropped hints that he intends -- as Aurora is tacitly hoping -- to set up deals."I look forward to working with Terry (CEO Terry Booth) and the extended Aurora team to evaluate its many operational and strategic opportunities," Peltz commented in the official statement, adding "including potential engagement with mature players in consumer and other market segments."Cowen analyst Vivien Azer agrees, writing of the news: "Peltz brings a network of relationships with large potential strategic companies that ACB could partner with across medical and consumer applications. In addition, we think ACB will be more patient in partnership selection than its peers, particularly regarding equity investment."Some investors are particularly celebrating the fact that Peltz brings a wealth of experience within the food and consumer goods segment.Trian [Peltz's hedge fund] has been involved with a number of consumer packaged goods companies such as PepsiCo (NASDAQ:PEP), Keurig Dr Pepper (NYSE:KDP), Procter & Gamble (NYSE:PG), Kraft Heinz (NYSE:KHC), Mondelez (NASDAQ:MDLZ), among others, noted GMP Securities consumer goods analyst Martin Landry, who upgraded ACB stock following the announcement. Landry goes on to explain: "We believe he could be instrumental in facilitating discussions with large consumer packaged goods companies."The two upsides are just the tangible manifestations of a much-bigger benefit Peltz brings to the table, however. Credibility (and Motivation)While Altria and Constellation are recognizable brand names, neither are established as dealmakers. They're interest in cannabis is largely self-serving, and their plans for their partnership are limited to the development of cannabis-based products.Not so for Nelson Peltz and Aurora Cannabis. He's a known dealmaker that some companies and many investors like to see get involved, especially when potential value has been locked up for too long.Peltz is also not limited to creating synergy between just two organizations. He's willing and able to establish as many partnership with as many entities as possible, without stirring up concerns that he may be building up his partners' competitors as well. He will be doing that, but at least all partners know where they stand, and that Aurora is looking to become a supplier to multiple customers. There's room for all of them, and Peltz will be able to make introductions ACB couldn't on its own. * 7 Top Stocks to Buy From Goldman Sachs' Secret Portfolio Perhaps more than anything else, however, Peltz wants the same thing existing Aurora Cannabis stock holders want -- for the share price to rise. He's being granted options for up to nearly 20 million shares of ACB stock at $7.74 a share, vested gradually over the next four years.So, Peltz doesn't make any real money unless the stock performs well. Bottom Line for ACB StockDon't misread the message. While this is certainly a big win for Aurora, the company remains a risky proposition for multiple reasons.One of them is that cannabis remains illegal at the federal level in the United States despite widespread state-level legalization. Pot's future, and the future of all its derivatives, is still a bit dazed and confused.There's also the not-so-small reality that cannabis and now cannabis-based products are quickly becoming a commodity, which could crimp margins for the debt-laden Aurora.Nevertheless, if Peltz can pull the right strings -- and he's certainly got strings to pull -- the bullish case for Aurora Cannabis stock is bolstered. It's not a reason in and of itself to buy the shares. But, for investors on the fence about stepping into a position, the hedge-fund player's news may be even bigger than the market realizes.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields Compare Brokers The post Aurora Cannabis, Nelson Peltz Tie-Up is Ultimately About One Thing appeared first on InvestorPlace.

  • 7 Dividend Stocks to Buy Today
    InvestorPlace7 days ago

    7 Dividend Stocks to Buy Today

    U.S. equities are pausing for breath on Thursday, amid nagging concerns about the fate of U.S.-China trade talks and ongoing woes for Boeing (NYSE:BA) after President Trump grounded the 787 MAX -- becoming the last country to do so after two fatal crashes of similar circumstances in the last five months.The drag on the Dow Jones Industrial Average, of which Boeing is a component, means that index hasn't gone anywhere in over a month. And zooming out further, it hasn't gone anywhere since last summer when the 25,500 level was first crossed in July. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% As investors wait for action, it's a perfect time to be reminded of the allure of dividend stocks which literally pay you to wait. While large-cap, big-tech growth stocks have been getting all the attention in recent years, there is still a place for value-focused dividend stocks. Here are seven dividend stocks to check out:InvestorPlace - Stock Market News, Stock Advice & Trading Tips Philip Morris International (PM)Philip Morris International (NYSE:PM) pays a dividend yield of 5.1%. On a technical basis, it's in clear uptrend territory: 3.5% above its 20-day moving average, 14.4% above its 50-day average, and 9.8% above its 200-day average. Shares were recently upgraded to buy by analysts at UBS, who are looking for a $101 price target.The company will next report results on April 18 before the bell. Analysts are looking for earnings of $1.02 per share on revenues of $6.8 billion. When the company last reported results on February 7, earnings of $1.25 beat estimates by nine cents on a 9.6% decline in revenues. Altria Group (MO)Shares of Altria (NYSE:MO) pay a dividend yield of 5.7%. The stock is on the move but not yet overextended: While above its 20-day and 50-day moving averages, its still below its 200-day average. * 7 Stocks to Buy With High ESG Momentum The company will next report results on April 25 before the bell. Analysts are looking for earnings of 94 cents per share on revenues of $4.6 billion. When the company last reported on January 31, earnings of 95 cents per share matches estimates on a 1.5% rise in revenues. The Williams Companies (WMB)Shares of The Williams Companies (NYSE:WMB) pay a dividend yield of 5.5%. The stock is above all three of its major moving averages, but remains 13.9% below its prior 52-week high. The energy pipeline play is well positioned to take advantage of the infrastructure shortage limiting the blitz of U.S. shale oil and gas activity.The company will next report results on May 1 after the close. Analysts are looking for earnings of 23 cents per share on revenues of $2.3 billion. When the company last reported on February 13, earnings of 19 cents per share missed estimates by five cents. Weyerhaeuser (WY)Weyerhaeuser (NYSE:WY) shares pay a dividend yield of 5.2%. Shares are above their 20-day and 50-day moving averages, but remain more than 14% below their 200-day average and nearly a third below the prior 52-week high. Shares recently enjoyed an upgrade by analysts at BMO Capital Markets and were initiated with a buy rating by analysts at Seaport Global Securities. * Are These 3 Airline Stocks in for a Smooth Flight or More Turbulence? The company will next report results on April 26 before the bell. Analysts are looking for earnings of 12 cents per share on revenues of $1.7 billion. When the company last reported on February 1, earnings of 10 cents per share missed estimates by two cents on a 10.3% drop in revenues. Seagate (STX)Seagate (NASDAQ:STX) shares pay a dividend yield of 5.3%. The company is quickly closing in on its 200-day moving average. Semiconductor and memory stocks have been perking up in recent weeks on reports of lean inventories across the industry and hopes of a resurgence of demand for digital devices as global manufacturing recovers.The company will next report results on May 1 after the close. Analysts are looking for earnings of 71 cents per share on revenues of $2.3 billion. When the company last reported on February 4, earnings of $1.41 beat estimates by 14 cents on a 6.6% drop in revenues. Invesco (IVZ)Invesco (NYSE:IVZ) shares pay a dividend yield of 6.2%. Shares are above both their 20-day and 50-day moving averages, but are still more than 12% below their 200-day average and more than 40% away from their prior 52-week high. Barclays analysts recently highlighted management's ongoing effort to find $475 million in cost savings, which would provide an earnings tailwind. * 15 Stocks Sitting on Huge Piles of Cash The company will next report results on April 25 before the bell. Analysts are looking for earnings of 49 cents per share on revenues of $861.5 million. When the company last reported on January 30, earnings of 44 cents per share missed estimates by 11 cents on an 8.5% drop in revenues. Nielsen Holdings (NLSN)Nielsen Holdings (NYSE:NLSN) shares pay a dividend yield of 5.2%. Shares are on a roll, above all three of their major moving averages as they close in on their prior 52-week high which remains 22% to the upside. The company is enjoying a lift thanks to the surge of television programming -- both over-the-air, cable, and streaming -- and the need for programmers to get solid audience data to make production decisions. Activist investor Elliott Management recently purchased a stake.The company will next report results on April 25 before the bell. Analysts are looking for earnings of 32 cents per share on revenues of $1.6 billion. When the company last reported on February 28 earnings of 28 cents per share missed estimates by 27 ents on a 5.8% drop in revenues.As of this writing, William Roth held no positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields Compare Brokers The post 7 Dividend Stocks to Buy Today appeared first on InvestorPlace.